U.S. markets open in 1 hour 4 minutes

  • S&P Futures

    4,363.75
    -15.00 (-0.34%)
     

  • Dow Futures

    34,164.00
    -109.00 (-0.32%)
     

  • Nasdaq Futures

    14,884.00
    -51.25 (-0.34%)
     

  • Russell 2000 Futures

    1,793.80
    -7.10 (-0.39%)
     

  • Crude Oil

    89.08
    -0.60 (-0.67%)
     

  • Gold

    1,930.80
    -5.80 (-0.30%)
     

  • Silver

    23.27
    -0.11 (-0.49%)
     

  • EUR/USD

    1.0608
    +0.0013 (+0.13%)
     

  • 10-Yr Bond

    4.5420
    0.0000 (0.00%)
     

  • Vix

    17.22
    +0.32 (+1.89%)
     

  • GBP/USD

    1.2183
    -0.0029 (-0.24%)
     

  • USD/JPY

    148.8410
    +0.0060 (+0.00%)
     

  • Bitcoin USD

    26,272.71
    +223.15 (+0.86%)
     

  • CMC Crypto 200

    562.37
    +2.86 (+0.51%)
     

  • FTSE 100

    7,641.94
    +17.95 (+0.24%)
     

  • Nikkei 225

    32,315.05
    -363.57 (-1.11%)
     

GoodRx Holdings, Inc. (GDRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks Equity Research
·2 min read

For the quarter ended March 2023, GoodRx Holdings, Inc. (GDRX) reported revenue of $183.99 million, down 9.5% over the same period last year. EPS came in at $0.07, compared to $0.10 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $181.87 million, representing a surprise of +1.16%. The company delivered an EPS surprise of +16.67%, with the consensus EPS estimate being $0.06.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how GoodRx Holdings, Inc. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Prescription transactions revenue: $134.90 million versus $134.11 million estimated by seven analysts on average.

  • Other Revenue: $4.50 million versus the seven-analyst average estimate of $10.29 million.

  • Subscription Revenue: $24.10 million versus $23.57 million estimated by seven analysts on average.

  • Pharma Manufacturer Solutions Revenue: $20.40 million versus $20.04 million estimated by six analysts on average.

View all Key Company Metrics for GoodRx Holdings, Inc. here>>>

Shares of GoodRx Holdings, Inc. have returned -19.3% over the past month versus the Zacks S&P 500 composite's +0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GoodRx Holdings, Inc. (GDRX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research